On October 20, 2023, InnoCan Pharma Corporation closed the transaction. The company issued 4,005,408 units at a price of CAD 0.3 per unit for the gross proceeds of CAD 1,201,622.4 in its final tranche. In total, the company issued an aggregate of 5,425,608 units under the offering for aggregate gross proceeds of CAD 1,627,682.40.

The company also paid the Agent a corporate finance advisory fee consisting of 122,500 Units, CAD 27,700 in cash and 92,330 Broker Warrants.